BRAF and glioma: Although we focused on the indication of anti-TIM3 in BRAF fusion PA, which accounts for the majority of pediatric gliomas, this could be further explored in high-grade, BRAF-driven gliomas such as pleomorphic xanthoastrocytoma (78).